Literature DB >> 26106084

Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA).

Sabine Bader1, Magdalena Zajac2, Thomas Friess1, Elisabeth Ruge1, Natascha Rieder1, Berthold Gierke3, Yvonne Heubach3, Marlene Thomas4, Michael Pawlak5.   

Abstract

Reverse phase protein arrays (RPPA) are an established tool for measuring the expression and activation status of multiple proteins in parallel using only very small amounts of tissue. Several studies have demonstrated the value of this technique for signaling pathway analysis using proteins extracted from fresh frozen (FF) tissue in line with validated antibodies for this tissue type; however, formalin fixation and paraffin embedding (FFPE) is the standard method for tissue preservation in the clinical setting. Hence, we performed RPPA to measure profiles for a set of 300 protein markers using matched FF and FFPE tissue specimens to identify which markers performed similarly using the RPPA technique in fixed and unfixed tissues. Protein lysates were prepared from matched FF and FFPE tissue specimens of individual tumors taken from three different xenograft models of human cancer. Materials from both untreated mice and mice treated with either anti-HER3 or bispecific anti-IGF-1R/EGFR monoclonal antibodies were analyzed. Correlations between signals from FF and FFPE tissue samples were investigated. Overall, 60 markers were identified that produced comparable profiles between FF and FFPE tissues, demonstrating significant correlation between the two sample types. The top 25 markers also showed significance after correction for multiple testing. The panel of markers covered several clinically relevant tumor signaling pathways and both phosphorylated and nonphosphorylated proteins were represented. Biologically relevant changes in marker expression were noted when RPPA profiles from treated and untreated xenografts were compared. These data demonstrate that, using appropriately selected antibodies, RPPA analysis from FFPE tissue is well feasible and generates biologically meaningful information. The identified panel of markers that generate similar profiles in matched fixed and unfixed tissue samples may be clinically useful for pharmacodynamic studies of drug effect using FFPE tissues.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26106084      PMCID: PMC4597151          DOI: 10.1074/mcp.O114.045542

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  49 in total

1.  Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues.

Authors:  Maria Filippa Addis; Alessandro Tanca; Daniela Pagnozzi; Salvatore Crobu; Giuseppe Fanciulli; Paolo Cossu-Rocca; Sergio Uzzau
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

Review 2.  Antibody-based proteomics: analysis of signaling networks using reverse protein arrays.

Authors:  Hans Voshol; Markus Ehrat; Jens Traenkle; Eric Bertrand; Jan van Oostrum
Journal:  FEBS J       Date:  2009-10-26       Impact factor: 5.542

3.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

4.  Multiplex immunoassays of peptide hormones extracted from formalin-fixed, paraffin-embedded tissue accurately subclassify pituitary adenomas.

Authors:  Frederick G Strathmann; Grace Borlee; Donald E Born; Luis F Gonzalez-Cuyar; Bertrand R Huber; Geoffrey S Baird
Journal:  Clin Chem       Date:  2011-12-28       Impact factor: 8.327

5.  Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Authors:  Rebecca Croasdale; Katharina Wartha; Juergen M Schanzer; Klaus-Peter Kuenkele; Carola Ries; Klaus Mayer; Christian Gassner; Martina Wagner; Nikolaos Dimoudis; Sylvia Herter; Christiane Jaeger; Claudia Ferrara; Eike Hoffmann; Lothar Kling; Wilma Lau; Roland F Staack; Julia Heinrich; Werner Scheuer; Jan Stracke; Christian Gerdes; Ulrich Brinkmann; Pablo Umana; Christian Klein
Journal:  Arch Biochem Biophys       Date:  2012-03-21       Impact factor: 4.013

6.  Macromolecular changes caused by formalin fixation and antigen retrieval.

Authors:  R W Dapson
Journal:  Biotech Histochem       Date:  2007-06       Impact factor: 1.718

7.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.

Authors:  Satoshi Nishizuka; Sing-Tsung Chen; Fuad G Gwadry; Jes Alexander; Sylvia M Major; Uwe Scherf; William C Reinhold; Mark Waltham; Lu Charboneau; Lynn Young; Kimberly J Bussey; Sohyoung Kim; Samir Lababidi; Jae K Lee; Stefania Pittaluga; Dominic A Scudiero; Edward A Sausville; Peter J Munson; Emmanuel F Petricoin; Lance A Liotta; Stephen M Hewitt; Mark Raffeld; John N Weinstein
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

8.  Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Authors:  Julia D Wulfkuhle; Daniela Berg; Claudia Wolff; Rupert Langer; Kai Tran; Julie Illi; Virginia Espina; Mariaelena Pierobon; Jianghong Deng; Angela DeMichele; Axel Walch; Holger Bronger; Ingrid Becker; Christine Waldhör; Heinz Höfler; Laura Esserman; Lance A Liotta; Karl-Friedrich Becker; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

9.  Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity.

Authors:  Grazia Saturno; Manuela Pesenti; Cristiano Cavazzoli; Anna Rossi; Anna M Giusti; Berthold Gierke; Michael Pawlak; Miro Venturi
Journal:  Toxicol Pathol       Date:  2007-12       Impact factor: 1.902

10.  Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.

Authors:  A R Green; D G Powe; E A Rakha; D Soria; C Lemetre; C C Nolan; F F T Barros; R D Macmillan; J M Garibaldi; G R Ball; I O Ellis
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

View more
  3 in total

Review 1.  Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.

Authors:  Yiling Lu; Shiyun Ling; Apurva M Hegde; Lauren A Byers; Kevin Coombes; Gordon B Mills; Rehan Akbani
Journal:  Semin Oncol       Date:  2016-06-15       Impact factor: 4.929

2.  Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

Authors:  Marina Willibald; Giuliano Bayer; Vanessa Stahlhut; Gereon Poschmann; Kai Stühler; Berthold Gierke; Michael Pawlak; Harald Seeger; Alfred O Mueck; Dieter Niederacher; Tanja Fehm; Hans Neubauer
Journal:  Oncotarget       Date:  2017-08-02

3.  Multiclass cancer classification in fresh frozen and formalin-fixed paraffin-embedded tissue by DigiWest multiplex protein analysis.

Authors:  Teresa Bockmayr; Gerrit Erdmann; Denise Treue; Philipp Jurmeister; Julia Schneider; Anja Arndt; Daniel Heim; Michael Bockmayr; Christoph Sachse; Frederick Klauschen
Journal:  Lab Invest       Date:  2020-06-29       Impact factor: 5.662

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.